Home » IsoRay Cans GliaSite Due to Low Sales
IsoRay Cans GliaSite Due to Low Sales
April 13, 2016
IsoRay has bid adieu to its GliaSite radiation therapy system and certain ancillary products, following “marginal sales” since its introduction, the company announced in a regulatory filing.
IsoRay has issued notices to end licensing agreements with Dr. Reddy’s Laboratories and Hologic and has slashed a distribution agreement with Karlheinz Goehl-Medizintechnik Goehl.
The system is designed to deliver brachytherapy radiation to treat brain cancer. — Anisa Jibrell
Upcoming Events
-
21Oct